From http://www.healthtalk.com/multiplescler ... page04.cfm
And Rebif, which in the most recent study - called the Evidence Study - comparing the effectiveness of Rebif to Avonex over a short time, at the end of 48 weeks the incidence of neutralizing antibodies to Rebif at the higher dosing was approximately 25 percent, whereas the incidence of neutralizing antibodies to Avonex in that same study was only 2 percent. In the packaging, Avonex has a neutralizing antibody incidence of 5 percent overall.
And from http://www.newswire.ca/en/releases/arch ... c4132.html
Previous clinical trial data has shown that Avonex(R) (interferon beta-1a
administered once weekly) consistently produces the lowest amount of
neutralizing antibodies among the available beta interferons. At a separate
symposium at the A/ECTRIMS meeting, Dr. Sorensen confirmed this finding by showing that in his study, 76% of Rebif(R) patients developed neutralizing antibodies, versus 33% of Betaseron(R) patients and only 11% of Avonex(R) patients, after three years of treatment.
The above is interesting: I had remembered Avonex with 10% neutralizing antibodies and Rebif with 20% but it looks like those numbers are higher - especially for Rebif. Patients have been dosed with Antegren for over 5 years now and I remember hearing Lars Eckman from Elan say 6%-7%, but cannot find that reference.